THMO - The Reincarnation Of ThermoGenesis With A Better Mousetrap For CAR-T Manufacturing

Introduction

Back in the 1990s, ThermoGenesis Holdings Inc. (THMO) was one of the early public company pioneers seeking to bring stem cell and regenerative medicine therapies to the market when it traded under the symbol KOOL. Primarily a cell processing device company, it eventually initiated a program in Critical Limb Ischemia using its own proprietary autologous cell processing technology and, like all other companies running clinical trials, ThermoGenesis had high hopes of success. In one clinical study, an autologous bone marrow cell dose was delivered into the afflicted leg artery of 13 patients